Okezie I Aruoma
As President and Chief Executive Officer, Dr Aruoma oversees the Corporate Affairs of Global PharmHealth Investors (GPHI) Inc, benchmarked on planning and directing all aspects of the Organization's policies, objectives, and initiatives including responsibility for the short- and long-term profitability and growth of GPHI. Dr Aruoma is a strong business development professional with a Master of Business Administration (M.B.A.) focused in Business Administration, Management and Operations from University of Warwick - Warwick Business School. Dr Aruoma is a Fellow of the Royal Society of Chemistry and a Chartered Scientist of the Science Council, UK. Fellowship of the Royal Society of Chemistry is the highest category of membership. Dr Aruoma is a Fellow of the American Association of Pharmaceutical Scientists, a Fellow of the American College of Nutrition and member of the UK’s Institute of Directors. Dr Aruoma is an accomplished international scientists and author of ten books including Molecular Biology of Free Radical in Human Diseases, DNA & Free Radicals: Techniques, Mechanisms and Applications and Free Radicals in Tropical Diseases and has had more than 250 papers published in high ranking scientific journals. Dr Aruoma has served as guest editor for numerous special issues in peer-reviewed scientific journals including Special Issue on Pharmacogenomics and Pharmacogenetics: Future of Biomarkers in Personalized Medicine; Toxicology; Special Issue on Dietary Nutraceuticals and Age Management Medicine, Preventive Medicine; and, Special Issue on Inflammation, cellular and redox signaling mechanisms in cancer and degenerative diseases, Mutation Research /Fundamental and Molecular mechanism of Mutagenesis. Dr Aruoma has over 28 years of experience in biomedical research focused on food biofactors, oxidative stress mechanisms, antioxidant pharmacology and the pharmaceutical indications of medicinal plants as prophylactic agents. Dr Aruoma’s expertise is directed at developing promising portfolio of biomarkers, food/pharmaceutical agents, safety and regulation pharmaceuticals and novel drug delivery system which have the potential to provide early diagnostic and preventative treatment for acute and chronic diseases with overt inflammation. Dr Aruoma will work closely with the Vice-presidents of the organization for the strategic planning and operational aspects of policies, objectives, and initiatives to enhance sustainability, profitability and growth of the of the organization, with experiences bench-marked on training in business administration and leadership in academia, research scholarship, technological innovation and entrepreneurship that caters for the sustainability of business enterprises. Dr Aruoma’s corporate responsibilities extend to the development of global education, global pharmacy and pharmaceutical drug development and global health initiatives as well as exploring funding opportunities to support research, scholarship and establishment of new business enterprises.